Sarepta Ready To Move Higher
November 19, 2012 | about: SRPT
Sarepta has a wonderful drug in its pipeline, which can dominate the market for years. Unlike many other drugs, Eteplirsen has support from the public who want this drug to be in the market. It has shown phenomenal results and may force the FDA to approve the drug without phase III trials. Regardless of early approval, the stock will continue to move up in the short and medium term. However, if the early approval is granted - the stock will move up rapidly. In addition, it is extremely unlikely that the company will face competition any time soon. I remain particularly optimistic and confident that Sarepta will provide massive returns to investors.
"FB IS CHEAP & TO RALLY SIGNIFICANTLY HIGHER" seeking alpha link.
Seeking Alpha 11/18
Now with the lockup being a concern of the past and the company showing near-term promise, it is likely that Facebook trades considerably higher. With the stock trading at 36.81x next year's earnings, which is very cheap for a social media stock, combined with the company finally returning profits with effective advertising on mobile and offering new services such as promoted feeds and Gifts, this is a stock that could rally significantly higher.